Drugs / Resiniferatoxin
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05695339 | Mar → Oct 2025 | Morton neuroma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT03542838 | Jul 2018 → Apr 2020 | osteoarthritis, knee | Sorrento Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03226574 | Sep 2017 → Mar 2020 | — | Sorrento Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02566564 | Apr 2016 → Jun 2017 | osteoarthritis, knee | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00804154 | Aug 2009 → Feb 2027 expected | — | National Institute of Dental and Craniofacial Research (NIDCR) | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02522611 | Jun → Dec 2026 expected | — | National Institute of Neurological Disorders and Stroke (NINDS) | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05067257 | Sep 2025 → Jun 2027 | neurological pain disorder | Sorrento Therapeutics, Inc. | Suspended | No outcome recorded |
| Phase 2 | NCT04885972 | Nov 2021 → Sep 2023 | osteoarthritis, knee | Sorrento Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04386980 | Apr 2021 → Jun 2022 | osteoarthritis, knee | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04044742 | Dec 2020 → Mar 2023 | chronic pain syndrome, osteoarthritis, knee | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04572776 | Dec 2020 → Mar 2023 | neurological pain disorder, neuropathy, painful | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resiniferatoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03542838 ↗ |
| Known as | Lopain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02566564 ↗ |
| Known as | Mtx-071 | ChEMBL registry synonym — accepted as the source's own label CHEMBL17976 ↗ |
| Known as | MTX-71 | ChEMBL registry synonym — accepted as the source's own label CHEMBL17976 ↗ |
| Known as | Neuroclastin | ChEMBL registry synonym — accepted as the source's own label CHEMBL17976 ↗ |
| Known as | RTX | “Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to...” NCT02522611 ↗2“This study will examine the safety of giving the experimental drug, resiniferatoxin (RTX), to treat severe pain in patients with advanced cancer.” NCT00804154 ↗ “study drug, resiniferatoxin (RTX)” NCT05695339 ↗ |
| Action | Activate | “a potent agonist of the transient receptor potential vanilloid 1 (TRPV1) ion channel” PMID 40423401 ↗ May 20251“Vanilloid receptor agonist” CHEMBL17976 ↗ |
| Modality | Other / unclassified | “Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.” NCT04572776 ↗ |
| Route | Intrathecal | “A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer” NCT00804154 ↗ |
| Target | TRPV1 | “Vanilloid receptor agonist” CHEMBL17976 ↗ |